James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Wedbush U-Turn on Tesla Stock Underscores a Problem for Investors

Tesla stock is so wild and unpredictable that it's forcing the best analysts to change course midstream.

7 Safe Stocks to Buy for Anxious Investors

If the market should move from bad to worse in the foreseeable future, these safe stocks to buy should shield you from the worst.

PayPal Is Impressive, But It’s the Wrong Time to Buy PayPal Stock

PayPal stock price may be a little too hot to handle just now, but the company itself is doing everything right.

3 Big Stock Charts for Tuesday: Synopsys, DISH Network and WellCare Health Plans

The stock charts of SNPS, WCG and DISH stock have been run through the technical trading wringer. Here's what you need to know.

ADBE Stock May Win the E-Commerce War … From Behind

Overshadowed by its cloud competitors, ADBE stock has an underappreciated ace up its sleeve with Adobe's Magento platform.

Taking a Shot on Ford Stock Now Wouldn’t Be Completely Crazy

Ford stock still has a few kinks to work out, but a closer, unbiased look reveals the carmaker has done what was needed to lift F stock.

Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock

Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.

3 Big Stock Charts for Monday: Davita, Clorox and Expedia Group

The stock charts of DVA, EXPE and CLX stock are primed to start the new trading week on a trade-worthy foot.

Why Facebook Stock Could Fall to $120

Pivotal Research Group analyst Brian Wieser remains steadfast that FB stock could get crushed if the company doesn't wake up.

3 Big Stock Charts for Friday: PPL, Electronic Arts and Tyson Foods

The stock charts of TSN, EA and PPL stock are going to end the week on the cusp of what could be trade-worthy moves.